SCHEMBL14039732

SCHEMBL14039732

CC(C)c1cc(C(C)C)c(S(=O)(=O)N[C@@H](Cc2cccc(C#N)c2)C(=O)O)c(C(C)C)c1

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.55
PLAU P00749 17/20 0.51
PLG P00747 14/20 0.51
ST14 Q9Y5Y6 4/20 0.51
F2 P00734 3/20 0.51
PLAT P00750 3/20 0.50
HPN P05981 2/20 0.49
HGFAC Q04756 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18049253 0.83 ST14 (0.74) F10PLAUPLGST14F2
SCHEMBL18049399 0.83 ST14 (0.74) F10PLAUPLGST14F2
SCHEMBL13866917 0.82 PLAU (0.78) F10PLAUPLGST14F2
SCHEMBL12618903 0.82 PLAU (0.78) F10PLAUPLGST14F2
SCHEMBL6266784 0.81 F10 (0.82) F10PLAUPLGST14F2
SCHEMBL13866546 0.81 F10 (0.55) F10PLAUPLGST14F2
SCHEMBL485675 0.80 MMP2 (0.66)
SCHEMBL485678 0.80 MMP2 (0.66)
SCHEMBL4588880 0.80 F10 (0.66) F10PLAUPLGST14F2
SCHEMBL19923004 0.79 MMP2 (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2022-06-02 US disclosed
US-11130780-B2 Inhibitors of growth factor activation enzymes WASHINGTON UNIVERSITY (US) 2021-09-28 US disclosed
US-20180066015-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2018-03-08 US disclosed
WO-2016144654-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2016-09-15 WO disclosed
US-20080261998-A1 Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors WILEX AG (DE) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130780-B2 Inhibitors of growth factor activation enzymes HDGF, MMP7, HGF F10 95/4885PLAU 46/4885PLG 91/4885
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES HDGF, MMP7, HGF F10 95/4885PLAU 46/4885PLG 91/4885
US-20080261998-A1 Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors PLAU, PLAUR, HPN F10 1217/4885PLAU 1/4885PLG 6/4885
US-20180066015-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES HDGF, MMP7, HGF F10 95/4885PLAU 46/4885PLG 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.